The US Food and Drug Administration has approved the first drug to help image tau neurofibrillary tangles in the brain, a primary marker of Alzheimer’s disease. The radioactive diagnostic agent, Tauvid (flortaucipir F18), is indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of the neurofibrillary tangles.
